S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate.


R-2-hydroxyglutarate accumulates to millimolar levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations. These levels of R-2-hydroxyglutarate affect 2-oxoglutarate-dependent dioxygenases. Both metabolite enantiomers, R- and S-2-hydroxyglutarate, are detectible in healthy individuals, yet their physiological function remains elusive. Here we show that 2-hydroxyglutarate accumulates in mouse CD8+ T cells in response to T-cell receptor triggering, and accumulates to millimolar levels in physiological oxygen conditions through a hypoxia-inducible factor 1-alpha (HIF-1α)-dependent mechanism. S-2-hydroxyglutarate predominates over R-2-hydroxyglutarate in activated T cells, and we demonstrate alterations in markers of CD8+ T-cell differentiation in response to this metabolite. Modulation of histone and DNA demethylation, as well as HIF-1α stability, mediate these effects. S-2-hydroxyglutarate treatment greatly enhances the in vivo proliferation, persistence and anti-tumour capacity of adoptively transferred CD8+ T cells. Thus, S-2-hydroxyglutarate acts as an immunometabolite that links environmental context, through a metabolic-epigenetic axis, to immune fate and function.

DOI: 10.1038/nature20165

6 Figures and Tables


Citations per Year

53 Citations

Semantic Scholar estimates that this publication has 53 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Tyrakis2016S2hydroxyglutarateRC, title={S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate.}, author={Petros A. Tyrakis and As{\'i}s Palaz{\'o}n and David Mac{\'i}as and Kian Leong Lee and Anthony T. Phan and Pedro Veliça and J. H. You and Grace Sushin Chia and Jingwei Sim and Andrew L Doedens and Alice Abelanet and Colin Edward Evans and John R. Griffiths and Lorenz Poellinger and Ananda W. Goldrath and Randall S Johnson}, journal={Nature}, year={2016}, volume={540 7632}, pages={236-241} }